MDxHealth SA (NASDAQ:MDXH) Given Average Rating of “Moderate Buy” by Analysts

MDxHealth SA (NASDAQ:MDXH) has been given a consensus recommendation of “Moderate Buy” by the five brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $7.75.

Several research analysts have commented on MDXH shares. Lake Street Capital upped their target price on shares of MDxHealth from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. BTIG Research reiterated a “buy” rating and set a $7.00 price objective on shares of MDxHealth in a research report on Tuesday, December 23rd. TD Cowen raised their target price on MDxHealth from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDxHealth in a research note on Monday, December 29th.

MDxHealth Stock Performance

MDXH stock opened at $3.71 on Tuesday. MDxHealth has a 1 year low of $1.35 and a 1 year high of $5.33. The stock has a market capitalization of $175.45 million, a price-to-earnings ratio of -5.80 and a beta of 1.62. The stock’s fifty day moving average is $3.48 and its two-hundred day moving average is $3.59.

MDxHealth (NASDAQ:MDXH) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The firm had revenue of $27.43 million for the quarter, compared to the consensus estimate of $24.11 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 30.50%. As a group, analysts predict that MDxHealth will post -1.15 EPS for the current fiscal year.

Hedge Funds Weigh In On MDxHealth

A number of institutional investors and hedge funds have recently bought and sold shares of MDXH. Kennedy Capital Management LLC bought a new stake in shares of MDxHealth during the 3rd quarter worth about $1,826,000. FreeGulliver LLC increased its stake in shares of MDxHealth by 104.7% during the third quarter. FreeGulliver LLC now owns 252,894 shares of the company’s stock valued at $1,176,000 after acquiring an additional 129,348 shares during the period. Mink Brook Asset Management LLC acquired a new position in shares of MDxHealth during the third quarter valued at approximately $743,000. Panoramic Capital LLC bought a new stake in MDxHealth during the third quarter worth approximately $721,000. Finally, Russell Investments Group Ltd. acquired a new stake in MDxHealth in the third quarter worth approximately $461,000.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.